keyword
MENU ▼
Read by QxMD icon Read
search

Haematology clinic

keyword
https://www.readbyqxmd.com/read/29040595/a-comparison-of-levofloxacin-and-oral-third-generation-cephalosporins-as-antibacterial-prophylaxis-in-acute-leukaemia-patients-during-chemotherapy-induced-neutropenia
#1
Kristyn E Yemm, Jason N Barreto, Kristin C Mara, Ross A Dierkhising, Naseema Gangat, Pritish K Tosh
Background: There is demonstrated benefit with fluoroquinolones as infection prophylaxis in neutropenic patients; however, side effects, drug interactions and increasing resistance necessitate investigation of alternative therapies. Objectives: To compare the incidence of febrile neutropenia in high-risk patients with haematological malignancy receiving a fluoroquinolone with those receiving an oral third-generation cephalosporin (OTGC) as antibacterial prophylaxis during chemotherapy-induced neutropenia...
October 11, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29034989/neurological-presentations-revealing-acquired-copper-deficiency-diagnosis-features-etiologies-and-evolution-in-seven-patients
#2
Aurélia Poujois, Nouzha Djebrani-Oussedik, Fabienne Ory-Magne, France Woimant
BACKGROUND: acquired copper deficiency (ACD) is a rare condition usually diagnosed from haematological changes. AIMS: characterize the diagnosis features and the evolution of patients with ACD revealed by neurological symptoms. METHODS: clinical, biological and MRI data were prospectively analysed at diagnosis and during follow-up under copper supplementation. RESULTS: seven patients were studied over a 5-year period...
October 16, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/29032616/a-survey-on-hematology-oncology-pediatric-aieop-centres-the-challenge-of-posterior-reversible-encephalopathy-syndrome
#3
Daniele Zama, Pietro Gasperini, Massimo Berger, Mariagrazia Petris, Maria D De Pasquale, Simone Cesaro, Maria E Guerzoni, Elena Mastrodicasa, Francesca Savina, Ottavio Ziino, Valentina Kiren, Paola Muggeo, Rosa M Mura, Fraia Melchionda, Giulio A Zanazzo
Posterior reversible encephalopathy syndrome (PRES) is one of the most common neurological complications in hematology-oncology pediatric patients. Despite an increasingly recognized occurrence, no clear consensus exists regarding how best to manage the syndrome, because most cases of PRES have reported in single case reports or small series. Aim of this paper is to identify incidence, clinical features, management and outcome of PRES in a large series of hematology-oncology pediatric patients METHODS: The cases of PRES occurred in twelve centres of the Italian Association of Pediatric Haematology and Oncology were reported RESULTS: 124 cases of PRES in 112 pediatric patients were recorded with an incidence of 2...
October 15, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/29032304/heterocyclic-homoprostanoid-derivative-attenuates-monoarthritis-in-rats-an-in-vitro-and-in-vivo-preclinical-paradigm
#4
Jayesh Mudgal, S A Manohara Reddy, Geetha Mathew, Anoop Kishore, C Mallikarjuna Rao, Gopalan K Nampurath
From our lab, among the nineteen heterocyclic homoprostanoids (HHPs), three derivatives (compounds 3, 3b and 3c) exerted antioxidant and anti-inflammatory activity. Present study is an extension of the earlier work, and, is designed to establish their therapeutic potential in monoarthritis in rats. In addition, their possible mechanism of action would be investigated. A battery of in vitro tests such as lipopolysaccharide (LPS)-induced nitrite (NO)/reactive oxygen species (ROS) and NO/interleukin (IL)-6 generation in murine macrophages and whole blood (WhB), respectively were conducted...
October 12, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29027832/clinical-evaluation-of-p-glycoprotein-inhibition-by-venetoclax-a-drug-interaction-study-with-digoxin
#5
Manoj S Chiney, Rajeev M Menon, Orlando F Bueno, Bo Tong, Ahmed Hamed Salem
1. Venetoclax is a novel, small molecule B-cell lymphoma-2 (BCL-2) inhibitor that has demonstrated clinical efficacy in a variety of haematological malignancies. Since venetoclax is an inhibitor of P glycoprotein (P-gp) transporter, a study was conducted in healthy, female volunteers to evaluate the effect of venetoclax on the pharmacokinetics of digoxin, a P-gp probe substrate. 2. Volunteers received a single oral dose of digoxin (0.5 mg) with or without a single oral dose of venetoclax (100  mg). Serial blood samples were obtained for pharmacokinetic assessments of digoxin and venetoclax and serial urine samples were obtained for measurement of digoxin concentrations...
October 13, 2017: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/29027199/characterization-of-a-mouse-model-of-sickle-cell-trait-parallels-to-human-trait-and-a-novel-finding-of-cutaneous-sensitization
#6
Katherine J Zappia, Yihe Guo, Dawn Retherford, Nancy J Wandersee, Cheryl L Stucky, Cheryl A Hillery
Sickle cell trait (SCT) has classically been categorized as a benign condition except in rare cases or upon exposure to severe physical conditions. However, several lines of evidence indicate that individuals with SCT are not always asymptomatic, and additional physiological changes and risks may remain unexplored. Here, we utilized mice harbouring one copy of normal human β globin and one copy of sickle human β globin as a model of SCT to assess haematological, histopathological and somatosensory outcomes...
October 12, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/29026400/hydroxyurea-therapy-in-adult-nigerian-sickle-cell-disease-a-monocentric-survey-on-pattern-of-use-clinical-effects-and-patient-s-compliance
#7
Ademola Samson Adewoyin, Omokiniovo Sunday Oghuvwu, Omolade Augustina Awodu
BACKGROUND: The clinical prospects of hydroxyurea therapy in the management of sickle cell disease (SCD) require evaluation in the Nigerian setting to develop indigenous guidelines. This survey examines the pattern of hydroxyurea therapy, its clinico-haematologic benefits and safety profile in Nigerian SCD subjects. METHODS: A cross sectional pilot survey was carried out among 60 adult SCD subjects over 3 months. Data on clinical phenotypes, relevant haematological parameters and details of hydroxyurea therapy were obtained using a structured questionnaire through an interview process and case file review...
March 2017: African Health Sciences
https://www.readbyqxmd.com/read/29025287/-incidence-and-treatment-of-extranodal-natural-killer-t-cell-lymphoma-nasal-type-hungarian-experiences
#8
Annamária Bakos, Árpád Szomor, Tamás Schneider, Zsófia Miltényi, Imelda Marton, Zita Borbényi, Judit Pammer, László Krenács, Enikő Bagdi, Klára Piukovics
INTRODUCTION: Extranodal natural killer/T (NK/T) cell lymphoma, nasal type (ENKTL) represents a rare subtype of T-cell lymphomas with aggressive clinical behavior according to WHO 2016 classification. AIM: ENKTL has distinctive geographic distribution with higher incidence in Asia and Latin America (10% of all non-Hodgkin lymphoma cases), than in Europe and North America (<1%). ENKTL tipically origins from nasopharynx and upper aerodigestive tract. Anthracycline-based chemotherapy regimens are largely ineffective in the treatment of ENKTL...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/29021147/atypical-haematological-presentation-in-a-case-of-polycythaemia-vera-with-a-new-variant-mutation-detected-in-exon-12-c-1605g-t-p-met535ile
#9
Amélia Soraia Andrade Pita, Ana Paula da Silva Azevedo, Alice Reichert, Cândido José Pimenta da Silva, Vanessa Henriques, Diana Sousa Mendes, Ana Maria Batalha Reis, Rita Cerqueira, Fátima Torres, João Faro Viana
One of the major genetic insights into the pathogenesis of polycythaemia vera included the identification of the somatic point gain-of-function mutations in Janus kinase 2 gene-first JAK2V617F on exon 14, present in 95%-97% of the cases, and later on exon 12. In the literature, we can find some reported studies where different exon 12 mutations are identified. Unlike patients with JAK2V617F mutation in exon 14, the mutation at exon 12 is not usually associated with an increase in the three haematopoietic series (erythrocytosis, leucocytosis and thrombocytosis)...
October 11, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29021143/cold-agglutinins-in-a-patient-undergoing-normothermic-cardiac-operation-with-warm-cardioplegia
#10
Tatsuhiko Ogawa
Cold agglutinins are autoantibodies that agglutinate red blood cells at low temperatures, leading to haemagglutination and haemolysis. They are generally of no clinical significance. However, when people with cold agglutinins undergo cardiac operation with hypothermia and cold cardioplegia, they can experience complications. Thus, different perioperative management is required for such patients. We describe a 74-year-old man with cold agglutinins incidentally detected on the preoperative screening test. He had never experienced any complications or developed a haematological disease...
October 10, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29020960/perspectives-in-immunotherapy-meeting-report-from-the-immunotherapy-bridge-napoli-november-30th-2016
#11
Paolo A Ascierto, Bruno Daniele, Hans Hammers, Vera Hirsh, Joseph Kim, Lisa Licitra, Rita Nanda, Sandro Pignata
The complex interactions between the immune system and tumors lead the identification of key molecules that govern these interactions: immunotherapeutics were designed to overcome the mechanisms broken by tumors to evade immune destruction. After the substantial advances in melanoma, immunotherapy currently includes many other type of cancers, but the melanoma lesson is essential to progress in other type of cancers, since immunotherapy is potentially improving clinical outcome in various solid and haematologic malignancies...
October 11, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29020888/clinical-haematology-and-biochemistry-profiles-of-cattle-naturally-infected-with-theileria-orientalis-ikeda-type-in-new-zealand
#12
K E Lawrence, S F Forsyth, B Vaatstra, A M J McFadden, D Pulford, K Govindaraju, W Pomroy
AIMS: To present the haematology and biochemistry profiles for cattle in New Zealand naturally infected with Theileria orientalis Ikeda type and investigate if the results differed between adult dairy cattle and calves aged <6 months. METHODS: Haematology and biochemistry results were obtained from blood samples from cattle which tested positive for T. orientalis Ikeda type by PCR, that were submitted to veterinary laboratories in New Zealand between October 2012 and November 2014...
October 11, 2017: New Zealand Veterinary Journal
https://www.readbyqxmd.com/read/29019736/clinical-and-laboratory-assessment-of-a-patient-with-thrombocytosis
#13
Niamh Appleby, Daniel Angelov
Elevated platelet counts are frequently encountered in hospital medicine and arise from both physiological and pathological mechanisms. Thrombocytosis may be secondary, reflecting an inflammatory state, iron deficiency, recent surgery or point towards an underlying neoplasm. Thrombocytosis may be the presenting sign of solid tumours and haematological conditions. The discovery of the activating mutations affecting thrombopoiesis led to greater understanding of the pathobiology of essential thrombocythaemia and other myeloproliferative neoplasms...
October 2, 2017: British Journal of Hospital Medicine
https://www.readbyqxmd.com/read/28990497/calr-jak2-and-mpl-mutation-status-in-argentinean-patients-with-bcr-abl1-negative-myeloproliferative-neoplasms
#14
Mara Jorgelina Ojeda, Irma Margarita Bragós, Karina Lucrecia Calvo, Gladis Marcela Williams, María Magdalena Carbonell, Arianna Flavia Pratti
OBJECTIVES: To establish the frequency of JAK2, MPL and CALR mutations in Argentinean patients with BCR-ABL1-negative  myeloproliferative neoplasms (MPN) and to compare their clinical and haematological features. METHODS: Mutations of JAK2V617F, JAK2 exon 12, MPL W515L/K and CALR were analysed in 439 Argentinean patients with BCR-ABL1-negative MPN, including 176 polycythemia vera (PV), 214 essential thrombocythemia (ET) and 49 primary myelofibrosis (PMF). RESULTS: In 94...
October 9, 2017: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/28983943/delayed-methotrexate-elimination-incidence-interaction-with-antacid-drugs-and-clinical-consequences
#15
Florence Ranchon, Nicolas Vantard, Emilie Henin, Emmanuel Bachy, Clémentine Sarkozy, Lionel Karlin, Fadhela Bouafia-Sauvy, Aurore Gouraud, Verane Schwiertz, Estelle Bourbon, Amandine Baudouin, Anne Gaelle Caffin, Thierry Vial, Gilles Salles, Catherine Rioufol
The aim of this retrospective cohort study was to investigate the incidence of delayed methotrexate elimination in patients treated with high-dose methotrexate (≥1 g/m(2) ) for haematological malignancy and to identify the impact of interacting drugs, especially proton-pump inhibitors (PPIs) and ranitidine. All patients treated with high-dose methotrexate over a 6 year period in the haematology department of the Lyon Sud University Hospital (Hospices Civils de Lyon, France) were included. Potential risk factors for delayed methotrexate elimination were tested in a generalized linear model by univariate analysis: patient age, gender, methotrexate dose, administration of PPI or ranitidine, and concomitant nephrotoxic drugs...
October 6, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28978170/imatinib-in-systemic-mastocytosis-a-phase-iv-clinical-trial-in-patients-lacking-exon-17-kit-mutations-and-review-of-the-literature
#16
Iván Alvarez-Twose, Almudena Matito, José Mário Morgado, Laura Sánchez-Muñoz, María Jara-Acevedo, Andrés García-Montero, Andrea Mayado, Carolina Caldas, Cristina Teodósio, Javier Ignacio Muñoz-González, Manuela Mollejo, Luis Escribano, Alberto Orfao
Resistance to imatinib has been recurrently reported in systemic mastocytosis (SM) carrying exon 17 KIT mutations. We evaluated the efficacy and safety of imatinib therapy in 10 adult SM patients lacking exon 17 KIT mutations, 9 of which fulfilled criteria for well-differentiated SM (WDSM). The World Health Organization 2008 disease categories among WDSM patients were mast cell (MC) leukemia (n = 3), indolent SM (n = 3) and cutaneous mastocytosis (n = 3); the remainder case had SM associated with a clonal haematological non-MC disease...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28969143/a-rare-case-of-primary-plasma-cell-leukaemia-with-monosomy-x
#17
Smita Surendra Masamatti, Aparna Narasimha, Archana C Shetty, C Vijaya
Primary Plasma Cell Leukaemia (pPCL) is a very rare and aggressive subtype of plasma cell dyscrasias with a very poor outcome and characterized by presence of >2x109/l circulating plasma cells. Overall incidence being 1%-2% of all malignant plasma cell diseases and 0.9% of all acute leukaemias. Patients with primary and secondary PCL have similar clinical features but differences do exist. Here we report a rare and interesting case diagnosed as primary PCL in a 44-year-old female with unusual clinical presentation and complex karyotyping...
August 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28962071/thrombopoietin-mimetics-for-patients-with-myelodysplastic-syndromes
#18
REVIEW
Helga Dodillet, Karl-Anton Kreuzer, Ina Monsef, Nicole Skoetz
BACKGROUND: Myelodysplastic syndrome (MDS) is one of the most frequent haematologic malignancies of the elderly population and characterised by progenitor cell dysplasia with ineffective haematopoiesis and a high rate of transformation to acute myeloid leukaemia (AML). Thrombocytopenia represents a common problem for patients with MDS. ranging from mild to serious bleeding events and death. To manage thrombocytopenia, the current standard treatment includes platelet transfusion, unfortunately leading to a range of side effects...
September 30, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28960809/acquired-haemophilia-in-cancer-a-systematic-and-critical-literature-review
#19
REVIEW
M Napolitano, S Siragusa, S Mancuso, C M Kessler
AIM: There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. METHODS: Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding...
September 27, 2017: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://www.readbyqxmd.com/read/28960260/h-ferritin-and-pro-inflammatory-cytokines-are-increased-in-the-bone-marrow-of-patients-affected-by-macrophage-activation-syndrome
#20
Piero Ruscitti, Paola Cipriani, Paola Di Benedetto, Vasiliky Liakouli, Onorina Berardicurti, Francesco Carubbi, Francesco Ciccia, Giuliana Guggino, Giovanni Triolo, Roberto Giacomelli
Macrophage activation syndrome (MAS) is hyper-inflammatory life-threatening syndrome, typically associated with high levels of serum ferritin. This is an iron storage protein including heavy (H) subunits and light (L) subunits, categorised on their molecular weight. The H-/L-subunits ratio may be different in tissues, depending on the specific tissue and pathophysiologic status. In this work, we analysed the bone marrow (BM) biopsies of adult MAS patients to assess the presence of: i. H-ferritin and L-ferritin; ii...
September 28, 2017: Clinical and Experimental Immunology
keyword
keyword
32486
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"